The Trials Were Extended: A lot has been said about the trials being extended and the significantly longer timeframe. From everything that I have read, I can find no reference anywhere that the FDA changed the guidelines. It appears to me that this information was just never brought to light by the former CEO. Keep in mind the FDA originally wanted 10 individuals in the trial and agreed to only five. At no point did the company ever state they were going to begin the trials on five patients at the same time; they where always going to be staggered to some degree. I do not see the disclosure of the FDA requirements for the trials to be significantly different from what was originally planned. Does anyone honestly believe that if the first patient shows any significant improvement, these timeframe delays will become meaningless. In my book this clarification has virtually no impact on the value of the stock.
Validity of Monkey Trials: I, as well as a significant number of others, originally got into NVIV based upon the results of the monkey trials. I wish the damn monkeys could talk. Bottom line is this, if the trials are accurate, then the human trials have a high chance of being successful. If the monkey trials are less than accurate, someone has some serious explaining to do. If this was the case, however, I would still be very enthusiastic about the stock due to the hydrogel and other products the company has.